|
Patent landscape, scope, and claims: |
Patent 10,695,336 (US) Scope & Claims: Ethanol-Responsive Bi-phasic MPH Extended-Release Methods and Dosing Ranges
US Patent 10,695,336 claims a set of method-of-treatment claims covering oral dosing regimens for conditions responsive to methylphenidate (MPH) (or salts) using a specific extended-release (ER) + rapid/immediate-release (IR) composite. The claimed ER component is constrained by a formulation-performance test: the ER release must show limited ethanol-driven acceleration (benchmarked in 40% ethanol/0.1N HCl at 37°C vs 0.1N HCl alone), and the ER release must meet defined percent released vs time targets (2h, 4h, 6h, 8h, 10h).
Across independent claim groupings, the scope centers on:
- A “less than X-fold ethanol-related increase” criterion (X=1.5 in early ER release total at first 120 minutes; X=2.0 for average rate between 15-120 minutes).
- A bi-phasic release composition: ER dominates (about 60–99% wt) with IR/rapid (about 1–40% wt), including specific fixed splits (about 18/82 and 22/78).
- Tied in vitro dissolution/release windows (20–30% at 1h; 25–35% at 2h; 45–60% at 4h; 68–85% at 6h; 90–100% at 8h; ~91–100% by 10h), plus an in vivo PK profile defined by Tmax, Cmax, AUCinf for specific dose/treatment contexts (fed/fasted/standard).
- Dose constraints: multiple claim sets recite discrete total MPH amounts (notably about 54 mg, 72 mg, and a broader 2.5–90 mg band in the broadest claim set).
- Salt constraint: MPH hydrochloride is explicitly covered.
- Use constraints: conditions listed as responsive to MPH include ADHD, narcolepsy, POTS, lethargy, fatigue, bipolar disorder, lack of attention, opioid-induced somnolence, major depressive disorder, and obesity.
Because the patent is a method-of-treatment patent that is tightly tethered to formulation performance and in vivo PK readouts, the legal “actionable” question for competitors is not only “does your product treat ADHD,” but “does your product match this ER+IR ethanol-sensitivity and release/PK profile.”
What is the claim scope of US 10,695,336 for methylphenidate extended-release bi-phasic products? (ethanol test, release windows, PK)
Core protected concept: an oral dosing method that uses at least one dosage form containing:
- an ER composition of MPH (or MPH salt), and
- a rapid release or immediate release composition of MPH (or MPH salt),
where the ER release is engineered to exhibit limited ethanol-related acceleration and specific percent-release kinetics.
What ethanol-related limitation is claimed?
The ER composition must show a formulation-defined behavior when challenged with ethanol.
What ER release curve targets are claimed?
For the ER portion, the claim specifies percent released ranges after exposure to aqueous 0.1 N HCl at 37±1°C.
In the independent claim group that uses the ~54 mg dose:
- ~25% to ~35% released by 2 hours
- ~45% to ~60% released by 4 hours
- ~65% to ~85% released by 6 hours
- ~85% to ~100% released by 8 hours
- no less than ~85% released by 10 hours
In the independent claim group that uses ~2.5 mg to 90 mg (broadest set), in vitro release profile is also recited using median/range structure:
- at 1h: 20–30%
- at 2h: 25–35%
- at 4h: 45–60%
- at 6h: 68–85%
- at 8h: 90–100%
- at 10h: 91–100%
(with the claim text also reflecting median/range variants across the tables shown).
What bi-phasic weight splits are claimed between rapid and extended release?
Claims explicitly cover multiple partitioning strategies between rapid and ER fractions of the total MPH payload.
The claimed wt ranges:
- Rapid: 1–40% wt, ER: 99–60% wt
- Rapid: 10–40% wt, ER: 90–60% wt
- Rapid: 15–35% wt, ER: 85–65% wt
- Rapid: 15–25% wt, ER: 85–75% wt
- Rapid: 15–20% wt, ER: 85–80% wt
- Rapid: ≤20% wt, ER: ≥80% wt
Plus fixed splits:
- Rapid ~18% wt, ER ~82% wt
- Rapid ~22% wt, ER ~78% wt
What salt forms are claimed?
- MPH hydrochloride is explicitly included.
What in vivo PK constraints are claimed?
At least one independent claim group ties infringement to oral dosing delivering a defined PK profile.
For the ~54 mg total dose grouping, the claim recites:
- Fed: Tmax 5.7 h, Cmax 16 ng/mL, AUCinf *180 hng/mL**
- Fasted: Tmax 2.3 h, Cmax 4.8 ng/mL, AUCinf *54 hng/mL**
- Standard: Tmax 6 h, Cmax 15 ng/mL, AUCinf *180 hng/mL**
For the ~72 mg total dose grouping, the claim recites a fasted “Standard parameter” set:
- Tmax 5.68 h, Cmax 20.6 ng/mL, AUCinf *218.1 hng/mL**
These PK recitals matter because, even though the formulation performance is the “technical” anchor, method patents can be read as requiring that the administered dosage produces the PK profile described.
What dose ranges are claimed?
Claims include discrete and broad total dose structures:
- Independent claim group uses about 54 mg total dose (with the corresponding PK set).
- Another independent claim group uses about 72 mg total dose (with corresponding PK set).
- A broader independent claim group includes:
- about 2.5 mg to about 90 mg
- and enumerates many specific dose points including 2.5, 5, 7.5, 9, 10, 12.5, 14, 15, 17.5, 18, 20, 25, 27, 30, 35, 36, 40, 45, 50, 54, 60, 63, 70, 72, 75, 80, 81, 90 mg.
What is the therapeutic use scope?
The condition is selected from a listed group:
- ADHD
- narcolepsy
- postural orthostatic tachycardia syndrome (POTS)
- lethargy
- fatigue
- bipolar disorder
- lack of attention
- opioid-induced somnolence
- major depressive disorder
- obesity
Key scope implication: the claim is not limited to ADHD-only; it is a broader MPH-responsive indications list.
How do claims 1 vs 9 vs 17 differ in US 10,695,336? (dose, PK table, breadth)
Claim set anchored to ~54 mg (Claim 1)
- ER ethanol limitation: <1.5-fold ethanol-related increase in total released in first 120 minutes.
- ER release curve windows: anchored to percent released at 2h/4h/6h/8h/10h.
- Bi-phasic split: ER/rapid wt ranges as listed.
- Dose: about 54 mg
- PK profile: includes fed/fasted/standard-like parameterization with:
- Fed Tmax 5.7, Cmax 16, AUCinf 180
- Fasted Tmax 2.3, Cmax 4.8, AUCinf 54
- Standard Tmax 6, Cmax 15, AUCinf 180
Claim set anchored to ~72 mg (Claim 9)
Same formulation constraints and release criteria structure, but with:
- Dose: about 72 mg
- PK set (fasted standard parameter):
- Tmax 5.68, Cmax 20.6, AUCinf 218.1
Broader dose and in vitro profile structure (Claim 17)
- Dose: about 2.5 mg to about 90 mg with extensive enumeration.
- Still requires ER ethanol limitation <1.5-fold and the ER release curve windows.
- Explicit in vitro release profile table included in Claim 17 itself (with time points 1,2,4,6,8,10 hours and % windows).
- Adds that the dosage form exhibits the in vitro release profile for both ER and rapid components combined per the table structure.
Practical scope effect: Claim 17 is the broadest infringement entry point for challengers and generic developers because it covers a wide dosing spectrum while preserving the most technical constraints (ethanol effect + release windows).
Which formulation attributes are actually “claim-limiting” for US 10,695,336? (ethanol sensitivity vs ER fraction vs release kinetics)
Claim 10,695,336 uses multiple layers of constraints. For freedom-to-operate analysis, the “must-match” constraints are typically:
-
ER ethanol acceleration cap
- “less than 1.5-fold” (total amount released first 120 minutes in 40% ethanol/0.1N HCl vs 0.1N HCl alone)
- and in some claim variants “less than 2-fold” (average rate from 15-120 min)
-
ER release percent vs time windows
- 2h/4h/6h/8h/10h ranges anchored to % released
-
bi-phasic composition mass split
- rapid fraction and ER fraction as wt % of the total dose
-
total dose
- exact ~54 mg or ~72 mg in certain claim sets
- broad 2.5–90 mg in broader set
-
MPH salt choice
- MPH hydrochloride explicitly covered (meaning that if a product uses another MPH salt, the claim literal scope depends on whether that salt falls within “MPH or salt thereof” language, which it does, but the dependent claim narrows to HCl)
-
PK profile
- recited for specific dose groupings; this can be argued as additional limiting evidence for method-level infringement
What’s comparatively less likely to be differentiating:
- The condition list is a use statement. If the drug is MPH and is administered for any listed condition, that element is easily satisfied.
- The “single dosage form daily” language in dependent claims is also common in marketed ER products.
What patents are likely in the landscape around US 10,695,336? (adjacent MPH ER, ethanol effect, biphasic release, and PK)
A complete landscape requires the full patent publication record for US 10,695,336 including application number, priority date, assignee, family members, and prosecution history. That information is not present in the input. With only the claim text provided, a non-speculative landscape mapping cannot be produced without fabricating other patent numbers.
Actionable focus from the claim text alone:
- The patent is directed to MPH ER formulations engineered for ethanol-limited acceleration and defined percent-release kinetics in acidic medium, and tied to bi-phasic dosing with rapid + ER fractions.
- Any competitor facing this patent will need to evaluate whether their ER granulation, coating, polymer matrix, or capsule/tablet design meets the specific ethanol and release constraints.
Therefore, the relevant “adjacent” patent categories that typically surround this kind of claim (without asserting specific patent numbers) are:
- ER MPH compositions with controlled release kinetics in simulated gastric fluid (SGF)
- biphasic immediate + extended MPH formulations
- studies or patents describing ethanol sensitivity or food effects on MPH release
- patents tying in vitro release to in vivo PK targets (Tmax/Cmax/AUC) for MPH ER products
- patents claiming specific dosing strengths as ranges linked to PK profiles
How strong is the patent estate for US 10,695,336 from a claim-construction standpoint? (breadth vs technical specificity)
Strength vector: high technical specificity
The claims are narrow in the sense that they require:
- a specific ethanol-response limitation,
- defined percent release windows at fixed times,
- defined ER/rapid weight splits,
- and dose/PK recitals for certain claim sets.
That specificity strengthens validity positions against prior art that teaches MPH ER generally but not the ethanol-sensitive release behavior.
Weakness vector: scope may be product-specific
A generic or reformulation can avoid literal coverage by:
- altering the ER matrix to change ethanol release acceleration above thresholds, or
- moving percent-release kinetics outside the claimed windows, or
- changing the rapid/ER weight split outside the claimed ranges, or
- changing strengths/dosing such that the particular method claim set is not met.
Litigation posture implication
In litigation, this patent will often pivot to:
- expert testing comparing release in 0.1 N HCl vs 40% ethanol/0.1 N HCl, and
- whether the accused dosage form’s ER fraction meets the <1.5-fold and/or <2-fold constraints,
- plus whether in vivo PK recitals are met for accused strengths.
What generic entry risks exist for MPH ER products under US 10,695,336? (Paragraph IV alignment with method-of-use claims)
Because US 10,695,336 is a method-of-treatment patent tied to administering a particular dosage form that meets exact formulation and PK characteristics, generic risk is not automatic merely by using MPH or by claiming an ER product. The risk emerges only if a generic product:
- uses an ER + rapid/immediate MPH design, with ER release showing the ethanol-insensitivity behavior claimed, and
- yields the claimed in vitro release profile, and
- uses dosing strengths (or range) that map to the claim’s dose limitations, and
- is administered for a condition within the listed group.
Commercial entry risk increases where:
- the generic is designed as a close “therapeutic equivalent” to a branded biphasic MPH ER product with known ethanol/food-release sensitivity patterns, and
- the generic chooses formulation approaches that are likely to land inside the claimed ER release windows.
How does US 10,695,336 define infringement mechanics: “administering” + formulation tests + PK?
The patent’s method framing means infringement requires both:
- Administration of the dosage form (daily, single dose form, oral), and
- That the dosage form administered has the claimed formulation performance characteristics (ethanol effect + release profile) and potentially the PK profile where recited.
This structure pushes disputes toward:
- compositional proof (is it ER + rapid?),
- release testing (ethanol assay),
- and sometimes PK cross-over matching for the relevant dose strengths.
Key Takeaways
- US 10,695,336 claims MPH method-of-treatment using an oral biphasic ER + rapid/immediate formulation where ER shows limited ethanol-driven acceleration in 40% ethanol/0.1N HCl at 37°C versus 0.1N HCl alone: <1.5-fold for total released in first 120 minutes and <2-fold for average release rate (in dependent variants).
- The ER release kinetics are constrained by fixed percent-release windows at 2, 4, 6, 8, and 10 hours.
- Claim scope depends materially on ER vs rapid wt partitioning (rapid 1–40% with many alternative bands; including fixed ~18/82 and ~22/78 splits).
- The broadest dose coverage runs ~2.5 mg to ~90 mg, while narrower claim sets anchor ~54 mg and ~72 mg with corresponding PK (Tmax, Cmax, AUCinf) recitals.
- The use list includes multiple MPH-responsive conditions beyond ADHD, including narcolepsy and mood-related diagnoses.
- For generic risk, the product must match the specific ethanol-release and release-kinetic constraints, not merely be an MPH ER tablet/capsule.
FAQs
1) Does US 10,695,336 require MPH hydrochloride specifically?
No. It covers “MPH or salt thereof” in the independent language; MPH hydrochloride is explicitly recited in dependent claims.
2) What is the key lab test for the ethanol limitation in US 10,695,336?
Release testing at 37±1°C comparing 0.1 N HCl vs 40% ethanol in aqueous 0.1 N HCl, with thresholds tied to first 120 minutes total released and (in dependent form) average rate from 15–120 minutes.
3) What time points must the extended release meet under the percent-release ranges?
The claims recite ER release targets by about 2, 4, 6, 8, and 10 hours (and the broader claim set also lists 1 hour).
4) Can a formulation avoid the patent by changing the rapid vs extended release weight split?
Yes in principle. The wt split is claimed in multiple bands, including fixed ~18/82 and ~22/78, so moving outside those partitions is a potential design-around.
5) Is PK profile a requirement for all claims?
No. PK is recited in certain independent claim groupings tied to specific total doses (notably ~54 mg and ~72 mg in the claim text provided). The release and ethanol constraints are central across the groups.
References (APA)
No external sources were provided for US Patent 10,695,336 beyond the claim text in the prompt, so no citable reference list can be generated.
More… ↓
⤷ Start Trial
|
